Back HIV/AIDS HIV/AIDS Topics HIV Treatment

AIDS 2016: Gains in Curbing HIV Could Be Lost Without Continued Commitment

Participants at the 21st International AIDS Conference (AIDS 2016), taking place this week in Durban, South Africa, reviewed the remarkable gains that have been made in access to HIV treatment and new prevention tools since the conference was last held here 16 years ago. But researchers, activists, and government leaders agreed that this progress could be reversed if stakeholders do not commit to increased funding and respect for the human rights of key populations at risk.

alt

Read more:

AIDS 2016: International AIDS Conference Starts Next Week in Durban

The 21st International AIDS Conference (AIDS 2016) opens next Monday, July 18, in Durban, South Africa, 16 years after the groundbreaking conference in the same city that put the spotlight on global access to new life-saving treatment for people living with HIV and AIDS. This year's theme -- Access, Equity, Rights Now -- recognizes the barriers that still need to be overcometo achieve universal access. HIVandHepatitis.comand collaborator Aidsmap.comwill provide on-site coverage starting on July 17. Follow @HIVandHepatitison Twitter and visit our AIDS 2016 conference page (coming soon) or Facebook pagefor the latest news.

alt

Read more:

AIDS 2016: International AIDS Conference Coming Up in Durban

The 21st International AIDS Conference (AIDS 2016) will take place July 18-22 in Durban, South Africa, 16 years after the groundbreaking conference in the same city that put the spotlight on global access to new life-saving treatment for people living with HIV and AIDS. This year's theme -- Access, Equity, Rights Now -- recognizes the barriers that still need to be overcometo achieve universal access. HIVandHepatitis.com and collaborator Aidsmap.com will provide comprehensive on-site coverage starting July 18. Follow @HIVandHepatitison Twitter and see our AIDS 2016 conference page (coming soon) or Facebook page for the latest news.

alt

Read more:

ASM Microbe 2016: Switching from Tenofovir DF to TAF Improves Bone and Kidney Safety

People with HIV who switched from the older tenofovir disoproxil fumarate (TDF) formulation to tenofovir alafenamide (TAF) were more likely to maintain viral load suppression and showed improvements in bone density and kidney function biomarkers, according studies presented at the 2016 ASM Microbe conference last month in Boston.

alt

Read more:

ASM Microbe 2016: New Integrase Inhibitor Bictegravir Looks Promising in Early Studies

Gilead Sciences' novel integrase inhibitor bictegravir (formerly GS-9883) demonstrated favorable pharmacokinetics, good tolerability, an improved resistance profile compared to older drugs in its class, and potent antiviral activity in laboratory and human studies, according to a set of posters presented at ASM Microbe 2016 last month in Boston.

alt

Read more:

ART Reduces Opportunistic Illnesses in Children and Adults with HIV

A pair of comprehensive reviews supported by the World Health Organization (WHO) have found that prompt initiation of antiretroviral therapy (ART) is associated with a lower risk of developing opportunistic infections and other HIV-related illnesses in children and adults living with HIV. Both reviews were published in the June 15 edition of Clinical Infectious Diseases.

alt

Read more:

Coverage of ASM Microbe 2016 (ICAAC 2016)

HIVandHepatitis.com coverage of ASM Microbe 2016 -- a new conference incorporating the American Society for Microbiology annual meeting and the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) -- Boston, June 16-20, 2016.

Highlights of this year's conference include antiretroviral drugs and treatment strategies, HIV pre-exposure prophylaxis (PrEP), microbiome research, antibiotic resistance, and emerging viruses including Zika.

Full coverage listing by topic

ASM Microbe 2016 website

7/1/16

alt